It would be unusual for a patient with advanced cancer not to be prescribed corticosteroids at some stage of their disease course for a variety of specific and non-specific indications.
Aim:
The aim of this practice review was to provide a pragmatic overview of the evidence supporting current practice and to identify areas in which further research is indicated.
Design:
A ‘state-of-the-art’ review approach was used to examine the evidence supporting the use of corticosteroids for the management of cancer-related complications and in symptom control, in the context of known risks and harms to inform quality use of this medicine. We developed ‘Do’, ‘Do not’, and ‘Don’t know’ recommendations based on current literature and identified areas for future investigation and research.
Data sources:
We searched MEDLINE, EMBASE and the Cochrane library from inception to 14th October 2020. Our initial search limited to reviews, reviews of reviews, randomised controlled trials (RCTs) and controlled trials was supplemented by supporting literature as appropriate.
Results:
Evidence to support common practice in the use of corticosteroids is lacking for most indications. This is in the context of strong evidence for the potential for significant toxicity and poor quality use of medicine.
Conclusion:
Guidelines recommending the widespread use of corticosteroids should acknowledge the poor evidence base supporting much current dogma. Quality research is essential not only to define the role of corticosteroids in this context but to ensure good prescribing practice.
HardyJRReesELingJ, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med2001; 15: 3–8.
2.
LundströmSHFürstCJ.The use of corticosteroids in Swedish palliative care. Acta Oncol2006; 45: 430–437.
3.
TwycrossR.The risks and benefits of corticosteroids in advanced cancer. Drug Saf1994; 11: 163–178.
4.
PinkertonEGoodPKindlK, et al. Quality use of medicines: oral corticosteroids in advanced cancer. Palliat Med2019; 33: 1325–1326.
5.
TwycrossR.Corticosteroids in advanced cancer. BMJ1992; 305: 969–970.
6.
Australian Government Department of Health. The national strategy for quality use of medicines. Plain English Edition. Canberra, ACT: Commonwealth of Australia, 2002.
7.
GrantMJBoothA.A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J2009; 26: 91–108.
8.
PluddemannAAronsonJKOnakpoyaI, et al. Redefining rapid reviews: a flexible framework for restricted systematic reviews. BMJ Evid Based Med2018; 23: 201–203.
HongQNGonzalez-ReyesAPluyeP.Improving the usefulness of a tool for appraising the quality of qualitative, quantitative and mixed methods studies, the Mixed Methods Appraisal Tool (MMAT). J Eval Clin Pract2018; 24: 459–467.
13.
LefroyJWatlingCTeunissenPW, et al. Guidelines: the do's, don'ts and don't knows of feedback for clinical education. Perspect Med Educ2015; 4: 284–299.
14.
KlimoPKestleJRSchmidtMH.Treatment of metastatic spinal epidural disease: a review of the literature. Neurosurg Focus2003; 15: E1.
15.
RykenTCMcDermottMRobinsonPD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol2010; 96: 103–114.
16.
VechtCJHovestadtAVerbiestHB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology1994; 44: 675–680.
17.
MulvennaPNankivellMBartonR, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet2016; 388: 2004–2014.
18.
VechtCJHaaxma-ReicheHVan PuttenWL, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology1989; 39: 1255–1257.
19.
GeorgeRJebaJRamkumarG, et al. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev2015; 2015: CD006716.
20.
KumarAWeberMHGokaslanZ, et al. Metastatic spinal cord compression and steroid treatment: a systematic review. Clin Spine Surg2017; 30: 156–163.
21.
FeuerDJBroadleyKE.Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev2000; 2000: CD001219.
22.
YamaguchiTGoyaSKoharaH, et al. Treatment recommendations for respiratory symptoms in cancer patients: clinical guidelines from the Japanese society for palliative medicine. J Palliat Med2016; 19: 925–935.
23.
KanELeviIBenharrochD.Alterations in the primary diagnosis of lymphomas pretreated with corticosteroid agents. Leukemia Lymphoma2011; 52: 425–428.
24.
National Institute for Health and Care Excellence. NICE clinical guideline CG75. Metastatic spinal cord compression in adults: risk assessment, diagnosis and management, https://www.nice.org.uk/guidance/cg75.
25.
BinnahilMAuKLuJQ, et al. The influence of corticosteroids on diagnostic accuracy of biopsy for primary central nervous system lymphoma. Can J Neurol Sci2016; 43: 721–725.
26.
ChyeRLickissN.The use of corticosteroids in the management of bilateral malignant ureteric obstruction. J Pain Symptom Manage1994; 9: 537–540.
27.
RémiCRémiJBauseweinC.Pharmacological management of bronchorrhea in malignant disease: a systematic literature review. J Pain Symptom Manage2016; 51: 916–925.
28.
MillerSMcNuttLMcCannM-A, et al. Use of corticosteroids for anorexia in palliative medicine: a systematic review. J Palliat Med2014; 17: 482–485.
29.
CurrowDCGlarePAWattsG, et al. Treating anorexia in people with advanced cancer. a randomised, double blind, controlled trial of megestrol acetate, dexamethasone or placebo. Support Care Cancer2018; 26: S198.
30.
OstwalSDeodharJ.Role of megestrol acetate versus dexamethasone for improvement in appetite in patients with cancer associated anorexia cachexia: a randomized controlled pilot trial. J Pain Symptom Manage2017; 53: 439–440.
31.
RoelandEJBohlkeKBaracosVE, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol2020; 38: 2438–2453.
32.
HaywoodAGoodPKhanS, et al. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database Syst Rev2015; 4: CD010756.
33.
WhitePArnoldRBullJ, et al. The use of corticosteroids as adjuvant therapy for painful bone metastases: a large cross-sectional survey of palliative care providers. Am J Hosp Palliat Care2018; 35: 151–158.
34.
FabregatCAlmendrosSNavarro-MartinA, et al. Pain flare-effect prophylaxis with corticosteroids on bone radiotherapy treatment: a systematic review. Pain Pract2020; 20: 101–109.
35.
RoilaFMolassiotisAHerrstedtJ, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol2016; 27: v119–v133.
36.
Vayne-BossertPHaywoodAGoodP, et al. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane Database Syst Rev2017; 7: CD012002.
37.
YennurajalingamS.Dexamethasone for symptom distress in advanced cancer: a double-blind, randomized, placebo-controlled trial (TH307-C). J Pain Symptom Manage2013; 45: 337.
38.
PaulsenOKlepstadPRoslandJH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol2014; 32: 3221–3228.
39.
BrueraEMoyanoJRSalaR, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage2004; 28: 381–388.
40.
BeniwalSKapoorASinghalMK, et al. A phase III randomized, placebo-controlled trial evaluating cancer-related fatigue in patients with advanced cancer treated with dexamethasone. Support Care Cancer2015; 23: S85.
41.
TomlinsonDRobinsonPDOberoiS, et al. Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis. Curr Oncol2018; 25: e152–e167.
42.
MückeMCuhlsHPeuckmann-PostV, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev2015; 2015: CD006788.
43.
ThiemARolkeRRadbruchL.Glucocorticoids and androgens for treatment of tiredness and weakness in palliative care patients: a systematic review. Schmerz2012; 26: 550–567.
44.
HaywoodADucJGoodP, et al. Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. Cochrane Database Syst Rev2019; 2: CD012704.
45.
MolassiotisABryanGCaressA, et al. Pharmacological and non-pharmacological interventions for cough in adults with respiratory and non-respiratory diseases: a systematic review of the literature. Respir Med CME2010; 3: 199–206.
46.
MolassiotisASmithJABennettMI, et al. Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough. Cough2010; 6: 9.
47.
ChowEMeyerRMDingK, et al. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol2015; 16: 1463–1472.
48.
PopielaTLucchiRGiongoF, et al. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol1989; 25: 1823–1829.
49.
NguyenJCaissieAZhangL, et al. Dexamethasone toxicity and quality of life in patients with brain metastases following palliative whole-brain radiotherapy. J Radiat Oncol2013; 2: 435–443.
50.
BrueraERocaECedaroL.Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep1985; 69: 751–754.
51.
MoertelCGSchuttAJReitemeierRJ, et al. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer1974; 33: 1607–1609.
52.
SchackeHDockeWDAsadullahK.Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther2002; 96: 23–43.
53.
ConnHOPoynardT.Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med1994; 236: 619–632.
54.
HempenCWeissEHessCF.Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?Support Care Cancer2002; 10: 322–328.
55.
DropchoEJSoongSJ.Steroid-induced weakness in patients with primary brain tumors. Neurology1991; 41: 1235–1239.
56.
WalshLJWongCAOborneJ, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax2001; 56: 279–284.
57.
HatanoYMatsuokaHLamL, et al. Side effects of corticosteroids in patients with advanced cancer: a systematic review. Support Care Cancer2018; 26: 3979–3983.
58.
Van StaaTPLeufkensHGCooperC.The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int2002; 13: 777–787.
59.
SturdzaAMillarB-ABanaN, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer2008; 16: 1041–1048.
60.
JessurunCACHulsbergenAFCChoLD, et al. Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know?J Neuro-Oncol2019; 144: 249–264.
61.
HeimdalKHirschbergHSletteboH, et al. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol1992; 12: 141–144.
62.
MercadanteSDavidFRiinaS, et al. Injustifiable use of gastroprotection in advanced cancer patients. Palliat Med2007; 21: 631–633.
63.
NielsenGLSorensenHTMellemkjoerL, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med2001; 111: 541–545.
64.
HanksGWTruemanTTwycrossRG.Corticosteroids in terminal cancer: a prospective analysis of current practice. Postgrad Med J1983; 59: 702–706.
65.
FongACCheungNW.The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract2013; 99: 277–280.
66.
PilkeyJStreeterLBeelA, et al. Corticosteroid-induced diabetes in palliative care. J Palliat Med2012; 15: 681–689.
67.
JawardLRO’NeilTAMarksA, et al. Differences in adverse effect profiles of corticosteroids in palliative care patients. Am J Hosp Palliat Care2019; 36: 158–168.
68.
IsmailMFLavelleCCassidyEM.Steroid-induced mental disorders in cancer patients: a systematic review. Future Oncol2017; 13: 2719–2731.
69.
FardetLPetersenINazarethI.Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry2012; 169: 491–497.
70.
WenPYSchiffDKesariS, et al. Medical management of patients with brain tumors. J Neurooncol2006; 80: 313–332.
71.
GoSIKooDHKimST, et al. Antiemetic corticosteroid rotation from dexamethasone to methylprednisolone to prevent dexamethasone-induced hiccup in cancer patients treated with chemotherapy: a randomized, single-blind, crossover phase III trial. Oncologist2017; 22: 1354–1361.
72.
BuckleyLGuyattGFinkHA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol2017; 69: 1521–1537.
73.
AllenCSYeungJHVandermeerB, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev2016; 10: CD001347.
74.
LallaRVLatortueMCHongCH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer2010; 18: 985–992.
75.
LoPiccoloJMehtaSALipsonEJ.Corticosteroid use and pneumocystis pneumonia prophylaxis: a teachable moment. JAMA Intern Med2018; 178: 1106–1107.
76.
SepkowitzKABrownAETelzakEE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA1992; 267: 832–837.
77.
SternAGreenHPaulM, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev2014; 2014: CD005590.
78.
Murray-BrownF.Steroid use in palliative patients in Plymouth, UK. Palliat Med2016; 30: S95.
79.
ThomsonAHTomlinsonMJ.Brain metastases and steroid reduction after radiotherapy. Palliat Med2004; 18: 665–666.
80.
MundellLLindemannRDouglasJ.Monitoring long-term oral corticosteroids. BMJ Open Qual2017; 6: e000209.
81.
VardyJLDhillonHMPondGR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol2015; 33: 4085–4092.
82.
VardyJChiewKSGalicaJ, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer2006; 94: 1011–1015.
83.
ArmstrongTSYingYWuJ, et al. The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the dexamethasone symptom questionnaire-chronic. Neuro Oncol2015; 17: 1114–1120.
84.
KingTSipaviciusJKlaricaD, et al. Strengthening the myeloma nursing network in Australia and New Zealand (ANZ): leading best supportive care. Clin Lymphoma Myeloma Leuk2019; 19: e345–e346.
85.
OteroMJToscano GuzmanMDGalvan-BanqueriM, et al. Utility of a trigger tool (TRIGGER-CHRON) to detect adverse events associated with high-alert medications in patients with multimorbidity. Eur J Hosp Pharm. Epub ahead of print 8 May 2020. DOI: 10.1136/ejhpharm-2019-002126.
86.
CzockDKellerFRascheFM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet2005; 44: 61–98.
LaRochelleGELaRochelleAGRatnerRE, et al. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med1993; 95: 258–264.
89.
MeikleAWTylerFH.Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med1977; 63: 200–207.
90.
ByynyRL.Withdrawal from glucocorticoid therapy. N Engl J Med1976; 295: 30–32.
91.
DentonAShawJ.Corticosteroid prescribing in palliative care settings: a retrospective analysis in New Zealand. BMC Palliat Care2014; 13: 7.
92.
SiderisSAounFMartinezCN, et al. Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients. J Endocrinol Invest2016; 39: 729–738.
93.
De SantisMSaadF. Practical guidance on the role of corticosteroids in the treatment of metastatic castration-resistant prostate cancer. Urology2016; 96: 156–164.
94.
SarinRMurthyV.Medical decompressive therapy for primary and metastatic intracranial tumours. Lancet Neurol2003; 2: 357–365.
95.
MercadanteSAielliFAdileC, et al. Sleep disturbances in patients with advanced cancer in different palliative care settings. J Pain Symptom Manage2015; 50: 786–792.
96.
GillinJCJacobsLSFramDH, et al. Acute effect of a glucocorticoid on normal human sleep. Nature1972; 237: 398–399.
97.
JakobsenGEngstromMHjermstadMJ, et al. The short-term impact of methylprednisolone on patient-reported sleep in patients with advanced cancer in a randomized, placebo-controlled, double-blind trial. Support Care Cancer. Epub ahead of print 2020. DOI: 10.1007/s00520-00020-05693-00526.
98.
OhdoS.Chronotherapeutic strategy: rhythm monitoring, manipulation and disruption. Adv Drug Deliv Rev2010; 62: 859–875.
99.
TatalovicMLehmannRCheethamM, et al. Management of hyperglycaemia in persons with non-insulin-dependent type 2 diabetes mellitus who are started on systemic glucocorticoid therapy: a systematic review. BMJ Open2019; 9: e028914.
100.
JacobPChowdhuryTA.Management of diabetes in patients with cancer. QJM2015; 108: 443–448.
101.
MatsuoNMoritaTIwaseS.Physician-reported corticosteroid therapy practices in certified palliative care units in Japan: a nationwide survey. J Palliat Med2012; 15: 1011–1016.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
